.jpg)
L'UMR-S 1144 change de nom en 2025 à l'occasion du nouveau contrat quinquennal (2025-2029) et devient "Optimisation Thérapeutique en Neuropharmacologie". Elle est située à la Faculté de Pharmacie de Paris (75006).
Organisée en quatre équipes, l'UMR-S 1144 est membre de la Fondation FondaMental.
Variability in drug response to lithium (Li+) is poorly understood and significant as only 40% of patients with bipolar disorder highly respond to Li+. Li+ can be transported by sodium (Na+) transporters in kidney tubules or red blood cells but its transport has not been investigated at the blood-brain barrier (BBB). Inhibition and/or transcriptomic strategies for Na+-transporters such as ...
Efficacy of drugs aimed at treating central nervous system (CNS) disorders rely partly on their ability to cross the cerebral endothelium, also called the blood-brain barrier (BBB), which constitutes the main interface modulating exchanges of compounds between the brain and blood. In this work, we used both, conventional pharmacokinetics (PK) approach and in situ brain perfusion technique to study the b...
A 2 years postdoctoral position (starting as soon as possible) funded both by the University Paris Descartes and a private pharmaceutical company is available in our Resarch Unit, in the team headed by Pr. Xavier Declèves dedicated to the study of the blood-brain barrier (BBB). See here for details ...
Magali CHARTIER (étudiante en master 2, équipe 2) a obtenu le prix au Mérite de la Chancellerie des Universités de Paris (Pharmacie) pour ses travaux de Master 2 intitulé « Etude de la tolérance aux effets neurorespiratoires et du sevrage au baclofène chez le rat ». ...
Le Projet R-LiNk « Optimizing response to Li treatment through personalized evaluation of individuals with bipolar disorder: the R-LiNk initiative » est lauréat à l'appel à projets H2020. R-LiNk est coordonné par le Pr Frank Bellivier, co-directeur de l'équipe 1. Il implique 15 partenaires dans 8 pays avec un budget de 7,7 millions d’&eu...
Diphenhydramine, a sedative histamine H1-receptor (H1R) antagonist, was evaluated as a probe to measure drug/H+-antiporter function at the blood-brain barrier. In situ brain perfusion experiments in mice and rats showed that diphenhydramine transport at the blood-brain barrier was saturable, following Michaelis-Menten kinetics with a Km = 2.99 mM and Vmax = 179.5&thins...
